Sumanta Pal is an Oncologist in Newport Beach, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Ashish Kamat is a Urologist in Houston, Texas. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Daniel Geynisman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Geynisman is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Elizabeth Plimack is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Plimack is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Sima Porten is a Urologist in San Francisco, California. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Rana Mckay is a Hematologist Oncology specialist and a Hematologist in San Diego, California. Dr. Mckay is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Mehmet Bilen is an Oncologist in Atlanta, Georgia. Dr. Bilen has been practicing medicine for over 18 years and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Bradley Carthon is an Oncologist in Atlanta, Georgia. Dr. Carthon has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy.

Omer Kucuk is an Oncologist in Atlanta, Georgia. Dr. Kucuk has been practicing medicine for over 51 years and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Prostatectomy.

Shilpa Gupta is an Oncologist in Cleveland, Ohio. Dr. Gupta is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Gamma Knife Radiosurgery, and Gastrostomy.

Michael Harrison is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Prostatectomy. Dr. Harrison is currently accepting new patients.

Morgan Roupret practices in Paris, France. Mr. Roupret is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Bladder Cancer, Nephrectomy, and Cystectomy.

Ajjai Alva is an Oncologist and a Hematologist in North Kansas City, Missouri. Dr. Alva is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Lymphadenectomy, and Nephrectomy. Dr. Alva is currently accepting new patients.

Daniel Castellano practices in Madrid, Spain. Mr. Castellano is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, Cystectomy, and Orchiectomy.

Takashi Kawahara practices in Yokohama, Japan. Mr. Kawahara is rated as an Elite expert by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Prostate Cancer, Hydronephrosis, Kidney Transplant, and Ureteroscopy.

Yair Lotan is a Urologist in Frisco, Texas. Dr. Lotan is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.